BioTime, Inc

What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Oct. 13, 2015, 12:45 PM
    | Oct. 13, 2015, 12:45 PM | 5 Comments
  • Sep. 28, 2015, 9:13 AM
    | Sep. 28, 2015, 9:13 AM
  • Mar. 19, 2015, 1:04 PM
    • Thinly-traded small cap BioTime (BTX +16.1%) jumps on a 4x surge in volume in (what appears to be) belated response to the March 9 announcement by Mount Sinai's Icahn School of Medicine that it is launching a large-scale research study of asthma using Apple's ResearchKit iPhone software. The Asthma Health app was developed by Mount Sinai in conjunction with LifeMap Solutions, a subsidiary of BioTime's LifeMap Sciences.
    • LifeMap Solutions is working with the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai to develop big data analytics algorithms to process the enormous volume of study data. Researchers hope that it will lead to new discoveries about asthma and improved chronic disease management.
    | Mar. 19, 2015, 1:04 PM | 1 Comment
  • Mar. 19, 2015, 12:47 PM
    | Mar. 19, 2015, 12:47 PM | 5 Comments
  • Sep. 24, 2014, 5:35 PM
    | Sep. 24, 2014, 5:35 PM
  • Sep. 9, 2014, 12:09 PM
    • Shares of thinly-traded nano cap BioTime (BTX +11.9%) jump on a 4x surge in volume. Prices are up almost 60% from the intermediate low of $2.33 on July 18.
    • CEO Michael D.West made a presentation at the Rodman & Renshaw Healthcare Conference this morning.
    • Monday, September 15, 2014 is the record date for holders of Asterias Biotherapeutics (OTCPK:ASTY +16.3%) Series A common stock to receive BTX warrants exercisable at $5.00 per share. Each share of Asterias Series A will receive 1.223657 warrants (8M warrants distributed to 6,537,779 ASTY shares).
    | Sep. 9, 2014, 12:09 PM | 4 Comments
  • Jul. 18, 2014, 12:45 PM
    | Jul. 18, 2014, 12:45 PM
  • Dec. 23, 2013, 1:21 PM
    • BioTime (BTX +2.3%) subsidiary Cell Cure Neurosciences gets a $1.74M grant for 2014 from Israel's OCS.
    • The funds will be used to develop OpRegen for the treatment of AMD.
    • The company intends to complete preclinicals and file an IND for the commencement of human trials next year.
    • Cell Cure notes that it will repay the grant plus interest via royalty payments to OCS. (PR)
    | Dec. 23, 2013, 1:21 PM
  • Apr. 19, 2013, 9:43 AM

    BioTime (BTX +4.7%) moves higher after announcing an exclusive licensing agreement with UCLA for the company's HyStem hydrogels which "deliver locally released growth factors to improve recovery from stroke." The company hopes the related research (performed by Dr. Tom Carmichael) will pave the way for an investigational new drug application with the FDA.

    | Apr. 19, 2013, 9:43 AM
  • Mar. 19, 2013, 12:51 PM

    BioTime (BTX -7.6%) takes a hit today after reporting late Monday a Q4 loss of $0.12 per share, compared with a loss of $0.11 per share in the same period last year. Revenues were $1.22M, also down from the prior-year quarter. Total revenue decreased by 9% Y/Y, primarily due to lower grant revenue stemming from the completion of it's research grant from the California Institute for Regenerative Medicine, and an overall decrease in the sale of research products.

    | Mar. 19, 2013, 12:51 PM
  • Jan. 10, 2013, 4:04 PM

    BioTime (BTX +4%) finishes the day higher after saying earlier that it's submitted its Clinical Investigation Protocol to European regulators to begin clinical testing of its Renevia stem cell delivery platform.

    | Jan. 10, 2013, 4:04 PM
  • Jan. 7, 2013, 1:15 PM

    Shares of Geron (GERN +2.5%) snd BioTime (BTX +7.6%) both rise today after BTX agrees to buy the intellectual property, including patents and patent applications, and other assets related to GERN's human embryonic stem cell programs. The financial terms of the deal were in a letter of intent announced back in mid-November.

    | Jan. 7, 2013, 1:15 PM
  • Nov. 16, 2012, 8:24 AM

    Geron (GERN) +7.4% premarket after agreeing to sell its shuttered embryonic stem cell assets to BioTime (BTX), according to a non-binding letter of intent. The deal comes a year after GERN shut down the world's first trial of embryonic stem cells in humans. BTX says it arranged for a $10M investment from an undisclosed private investor to finance the proposed deal.

    | Nov. 16, 2012, 8:24 AM
  • Oct. 19, 2012, 12:23 PM

    Geron's (GERN -7.9%) board acknowledges receiving a letter from BioTime (BTX -3.3%) offering to buy its stem cell assets, saying it will review and act in a manner that it believes will be in the best interests of GERN's stockholders. The board adds that it's been considering a number of alternatives since its announcement earlier this month that it was discontinuing its stem cell research and development programs.

    | Oct. 19, 2012, 12:23 PM
  • Oct. 18, 2012, 9:18 AM

    Geron (GERN) +5.8% premarket after BioTime (BTX) issues an open letter to GERN shareholders proposing a transaction between the two biopharma companies. Part of the proposal would allow GERN shareholders could own up to 45% of a new publicly traded company that would own GERN stem cell assets.

    | Oct. 18, 2012, 9:18 AM | 1 Comment
  • Apr. 11, 2012, 2:59 PM

    BioTime (BTX -9.3%) shares sink after a Seeking Alpha article by Martin Shkreli says the biotech smallcap is worth ~$20M vs. its current ~$221M market cap. "With only $22M in cash and limited operations... BioTime has a need for raising cash in the future... I predict BTX shares will drop at least 50% in the next 12 months."

    | Apr. 11, 2012, 2:59 PM | 2 Comments
Company Description
BioTime Inc is a biotechnology company. The Company is engaged in the biomedical research and product development in regenerative medicine including human embryonic stem cell and induced pluripotent stem cell technology.
Sector: Healthcare
Industry: Biotechnology
Country: United States